You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
SB 200646 hydrochloride
Biological Activity for SB 200646 hydrochloride
SB 200646 hydrochloride is a 5-HT2C/2B receptor antagonist, selective over 5-HT1A. Affinities are 7.4 (pA2), 6.9 (pKi) and 5.2 (pKi) for 5-HT2B, 2C and 2A respectively. Orally active in vivo.
Sold under license
Technical Data for SB 200646 hydrochloride
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for SB 200646 hydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for SB 200646 hydrochloride
The following data is based on the product molecular weight 302.76. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.3 mL||16.51 mL||33.03 mL|
|5 mM||0.66 mL||3.3 mL||6.61 mL|
|10 mM||0.33 mL||1.65 mL||3.3 mL|
|50 mM||0.07 mL||0.33 mL||0.66 mL|
Product Datasheets for SB 200646 hydrochloride
References for SB 200646 hydrochloride
References are publications that support the biological activity of the product.
Forbes et al (1993) N-(1-Methyl-5-indolyl)-N'-(3-pyridyl)urea hydrochloride: the first selective 5-HT1C receptor antagonist. J.Med.Chem. 36 1104 PMID: 8478907
Kennett et al (1994) In vivo properties of SB 200646A, a 5-HT2C/2B recepor antagonist. Br.J.Pharmacol. 111 797 PMID: 7912626
Kennett et al (1995) Effect of SB 200646A, a 5-HT2C/5-HT2B receptor antagonist, in two conflict models of anxiety. Psychopharmacology (Berl.) 118 178 PMID: 7617805
If you know of a relevant reference for SB 200646 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: SB 200646 hydrochloride, SB 200646 hydrochloride supplier, 5-HT2C/2B, antagonists, Serotonin, 5-HT2B, Receptors, SB200646, hydrochloride, 5-HT2C, 1371, Tocris Bioscience
1 Citation for SB 200646 hydrochloride
Citations are publications that use Tocris products. Selected citations for SB 200646 hydrochloride include:
Xiao et al (2008) Release of glutamate and CGRP from trigeminal ganglion neurons: Role of calcium channels and 5-HT1 receptor signaling. Am J Physiol Endocrinol Metab 4 12 PMID: 18416824
Do you know of a great paper that uses SB 200646 hydrochloride from Tocris? Please let us know.
Reviews for SB 200646 hydrochloride
There are currently no reviews for this product. Be the first to review SB 200646 hydrochloride and earn rewards!
Have you used SB 200646 hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.